Cloperidone
Cloperidone acts as an inhibitor and substrate of CYP2C9, with an IC50 of 17.7 μM. Cloperidone exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 4052-13-5
- Formule: C21H23ClN4O2
- Masse moléculaire:398.89
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
CYP2C9 17.7 μM (IC50) |
Cloperidone (0.3-100 μM; 6 min preincubation, 15 min incubation with substrate) potently inhibits recombinant CYP2C9 microsomes, with an IC50 of 17.7 μM[1].
Cloperidone (0-60 min) can be metabolized by recombinant CYP2C9 supersomes to produce a variety of distinct oxidative metabolites[1].
Cloperidone (100 μM) exhibits enhanced cytotoxicity in HepG2 cells expressing CYP2C9, reducing cell viability to 40% of the baseline level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 4052-13-5
-
Masse moléculaire 398.89
-
Formule C21H23ClN4O2
-
SMILES
O=C1NC2=C(C(N1CCCN3CCN(CC3)C4=CC(Cl)=CC=C4)=O)C=CC=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Goldwaser E, et al. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9. PLoS Comput Biol. 2022 Jan 26;18(1):e1009820. [Content Brief]
[2]. Estrada E, et al. Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. Journal of computer-aided molecular design. 1998 Nov;12(6):583-95. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)